Beta Bionics, Inc. - Common Stock (BBNX)

Revenue hit $35.5 million with 30% growth as Mint patch pump nears Q1 2027 launch.

Beta Bionics (NASDAQ:BBNX) reported third-quarter net sales of $35.5 million, up about 30% from a year earlier, as new patient starts and recurring revenue from its pharmacy-channel user base supported growth. The company also raised the lower end of its full-year revenue outlook and outlined plans

Pharmacy channel sales surged 153% as new patient starts accelerated.

Beta Bionics (NASDAQ:BBNX) reported second-quarter 2026 net sales of $32 million, up approximately 38% from a year earlier, as new patient starts and recurring pharmacy-channel supply revenue supported growth for its iLet insulin-delivery system. Chief Executive Officer Sean Saint said the company’

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.

Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.

Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform. Speaking at a Bank of

Beta Bionics BBNX Q1 2026 Earnings Transcript

Beta Bionics (BBNX) Q4 2025 Earnings Transcript

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Beta Bionics (BBNX) Q3 2025 Earnings Transcript

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.